Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 6,59 M
EBIT 2017 -0,98 M
Net income 2017 -0,37 M
Debt 2017 -
Yield 2017 -
Sales 2018 8,32 M
EBIT 2018 -1,83 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 7,45x
Capi. / Sales2018 5,90x
Capitalization 49,1 M
More Financials
Company
IntelGenx Technologies Corp. operates as a drug delivery company.It focuses on the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.The company is a provider of product development services for the pharmaceutical industry,... 
Sector
Pharmaceuticals
Calendar
05/16Earnings Release
More about the company
Latest news on INTELGENX TECHNOLOGIES COR
03/29 INTELGENX TECHNOLOGIES : Oral Film Exclusivity Granted to IntelGenx' VersaFilm f..
03/29 INTELGENX TECHNOLOGIES : Reports Fourth Quarter and Full Year 2016 Financial Res..
03/28 INTELGENX TECHNOLOGIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
03/28 INTELGENX TECHNOLOGIES : Reports Fourth Quarter and Full-Year 2016 Financial Res..
03/28 INTELGENX TECHNOLOGIES CORP. (OTCMKT : IGXT) Files An 8-K Other Events
03/28 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
03/28 INTELGENX TECHNOLOGIES : Oral Film Exclusivity Granted to IntelGenx' VersaFilm(T..
03/28 INTELGENX TECHNOLOGIES : Oral Film Exclusivity Granted to IntelGenx' VersaFilm(T..
03/21 INTELGENX TECHNOLOGIES : to Report Fourth Quarter and Full Year 2016 Financial R..
03/21 INTELGENX TECHNOLOGIES : to Report Fourth Quarter and Full Year 2016 Financial R..
More news
Sector news : Generic Pharmaceuticals
05:01p China's Creat makes 1.2 billion euro bid for German blood plasma firm
11:07aDJOXFORD BIOMEDICA : Hails U.S. Regulatory Boost for Leukemia Treatment
03/29 FDA, Mylan silence on generic Advair may be good news for GSK
03/29 British business navigates rocky path to Brexit
03/29 ConvaTec's majority investors raise $1.2 billion via stake sale
More sector news : Generic Pharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus BUY
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Horst G. Zerbe Chairman, President & Chief Executive Officer
André Godin Chief Financial Officer & Executive Vice President
Nadine Paiement Director-Research & Development
Bernd Josef Melchers Independent Director
John Archibald Troup Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INTELGENX TECHNOLOGIES..49
OTSUKA HOLDINGS CO LTD2.69%26 231
SUN PHARMACEUTICAL IND..11.01%25 411
ONO PHARMACEUTICAL CO...-6.49%12 675
ASPEN PHARMACARE HOLDI..-3.33%9 594
SHANGHAI FOSUN PHARMAC..21.61%9 470
More Results